0 Replies
Hørsholm, Denmark / San Diego, California, April 16, 2013 — Santaris Pharma A/S, a privately held biopharmaceutical company focused on developing medicines targeted to disease-related mRNAs and microRNAs, today announced a worldwide strategic alliance with Bristol-Myers Squibb (NYSE: BMY) to discover and develop novel medicines using Santaris Pharma’s proprietary... Contine Reading & Discuss→
0 Replies
Santaris Pharma NEJM press release_3-21-13 FINAL.pdf
Hørsholm, Denmark/San Diego, California, March 27, 2013 — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the publication of study results online in the New England Journal of Medicine (NEJM).
read more Contine Reading & Discuss→
0 Replies
Research Published in the New England Journal of Medicine Demonstrates Marked and Long-Lasting Antiviral Activity Against HCV for Santaris Pharma A/S’ Miravirsen, the First MicroRNA-Targeted Drug to Enter Clinical Trials
HOERSHOLM, Denmark and SAN DIEGO, March 27, 2013 /PRNewswire/ — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the... Contine Reading & Discuss→
0 Replies
Santaris-miRagen Expanded Agreement 010813 FINAL.pdf
Hørsholm, Denmark / Boulder, Colorado USA, January 8, 2013. — Santaris Pharma A/S and miRagen Therapeutics, Inc. today announced that they have expanded their existing partnership in the field of microRNA therapeutics.
read more Contine Reading & Discuss→
0 Replies
Santaris New Release January 7.pdf
Hørsholm, Denmark / San Diego, California, January 7st, 2013. — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the USPTO has issued an Order granting their request for inter-partes re-examination of US patent 7,838,504... Contine Reading & Discuss→
0 Replies
Court Focuses Patent Suit on Santaris Safe Harbor Defense
Hørsholm, Denmark / San Diego, California, September 21st, 2012. — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the federal court in the Southern District of California granted Santaris significant... Contine Reading & Discuss→
0 Replies
Santaris Pharma press release June 20 2012 UK final.pdf
Hørsholm, Denmark/San Diego, California, June 20, 2012 — Santaris Pharma A/S, a clinical-stage biopharmaceutical Company focused on the discovery and development of RNA-targeted therapies, today announced that it has completed a new $12 million (DKK 70 million) private investment round structured... Contine Reading & Discuss→
0 Replies
April 25th News Release: New CEO
Hørsholm, Denmark, April 25th, 2012. — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that Søren Tulstrup, President and Chief Executive Officer, has decided to leave the company per April 30, 2012, to pursue other opportunities. Henrik... Contine Reading & Discuss→
0 Replies
SantarisPharmaUSPTOwinsFINAL.pdf
United States Patent and Trademark Office (USPTO) rules in favor of Santaris Pharma A/S in patent re-examination cases for two key Santaris Pharma A/S “Imanishi” patents
Patents cover the 2’-4’ bicyclic nucleotides known as LNA (Locked Nucleic Acid) or BNA (Bicyclic Nucleic Acid) chemistry that Santaris Pharma... Contine Reading & Discuss→
0 Replies
SantarisPharmaAASLDPhase2dataFINALpressrelease11.5.11.pdf
-- New Phase 2a clinical data to be presented in late-breaking oral presentation at AASLD –
read more Contine Reading & Discuss→
